RDHL

RedHill Biopharma Ltd.

$0.38

-5.04%

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

Source: Yahoo Finance
Q-Score27/ 100
Market Cap$3.3M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta0.62
AI summary

Price & performance

1M-16.8%
3M-36.0%
YTD-59.6%
1Y-67.3%
52-week range—
Beta0.62
Full chart and returns against a benchmark

Q-Score

27/ 100

Quality against peers; 50 is the peer median.

Growth41
Risk27
Performance35
Valuation32
Profitability49
Leverage8
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2024

Revenue$8M+23.2%
Net income-$8.3M-134.6%
Net margin-102.8%-469.0 pts
Historical fundamentals

Red flags in filings

1active red flag
Material weakness in controlsApr 27, 2026
Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

RDHLIndustryP/E—35.25P/S0.352.74EV/EBITDA—16.35P/B—2.46PEG—0.87
Dividend yield0.00%
Every valuation metric